{
  "id": 8083144,
  "title": "Bristol Myers scraps $100M Orum-partnered cancer drug",
  "url": "https://urgent.news/2026/09/17/bristol-myers-scraps-100m-orum-partnered-cancer-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T19:19:36.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/bristol-myers-scraps-orum-partnered-cancer-drug/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Bristol Myers Squibb has ended development of a twist on the popular antibody-drug conjugate field. The Phase 1 asset that was axed is BMS-986497/ORM-6151, according to a Thursday regulatory filing from ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}